Valuation: Arctic Bioscience

Market Cap 72.78M 7.62M 6.62M 6.15M 5.67M 10.68M 727M 10.87M 72.76M 28.49M 361M 28.61M 27.99M 1.21B P/E 2026 *
-3.03x
P/E 2027 * -
Enterprise Value 139M 14.53M 12.62M 11.72M 10.81M 20.36M 1.39B 20.73M 139M 54.32M 689M 54.56M 53.37M 2.32B EV / Sales 2026 *
2.39x
EV / Sales 2027 * -
Free-Float
47.75%
Yield 2026 *
-
Yield 2027 * -
1 day-3.57%
1 week-3.57%
Current month-16.67%
1 month-16.67%
3 months-18.18%
6 months-21.74%
Current year-17.68%
1 week 2.7
Extreme 2.7
2.8
1 month 2.57
Extreme 2.57
3.4
Current year 2.57
Extreme 2.57
3.67
1 year 2.57
Extreme 2.57
4.65
3 years 1.65
Extreme 1.65
16.8
5 years 1.65
Extreme 1.65
21.7
10 years 1.65
Extreme 1.65
32
Manager TitleAgeSince
Chief Executive Officer 60 2010-12-31
Chief Executive Officer 54 2022-02-28
Director of Finance/CFO 47 2022-03-31
Director TitleAgeSince
Chairman 68 2015-11-30
Director/Board Member 55 2014-12-31
Director/Board Member 46 2020-12-31
Date Insider Type Main position Quantity % Market Cap.
4/24/23 Buy

Director

943,833 3.8641%
4/24/23 Buy

Director

943,833 3.8641%
2/23/23 Buy

Chief Technology Officer

11,500 0.0472%
Change 5-day change 1-year change 3-year change Capi.($)
-3.57%-3.57%-22.64%-74.88% 7.62M
-4.55%-2.61%+51.95%+151.91% 1,030B
-3.66%-1.33%+52.95%+46.62% 617B
-2.24%+0.19%+35.97%+70.64% 455B
+0.88%+0.48%+38.78%+31.86% 350B
+0.85%+0.85%+35.87%+40.53% 299B
+0.79%+1.20%+13.23%+14.63% 265B
+0.18%+3.21%+5.21%-39.41% 225B
0.00%+4.34%+28.63%+64.00% 209B
-1.09%+0.32%+14.40%+70.80% 163B
Average -0.75%+4.24%+25.44%+37.67% 361.27B
Weighted average by Cap. -0.63%+4.87%+38.70%+72.11%

Financials

2026 *2027 *
Net sales 58M 6.07M 5.27M 4.9M 4.52M 8.51M 580M 8.66M 57.98M 22.7M 288M 22.8M 22.3M 968M -
Net income -24M -2.51M -2.18M -2.03M -1.87M -3.52M -240M -3.58M -23.99M -9.39M -119M -9.44M -9.23M -401M -
Net Debt 66M 6.91M 6M 5.57M 5.14M 9.68M 660M 9.86M 65.98M 25.83M 328M 25.95M 25.38M 1.1B -
Logo Arctic Bioscience
Arctic Bioscience AS is a Norway-based biotech company developing and commercializing both pharmaceutical and nutraceutical products based on the properties of herring roe oil. Arctic Bioscience’s purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The Company is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The Company's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.
Employees
19
Date Price Change Volume
26-07-30 NOK 2.700 -3.57% 40,482
26-07-29 NOK 2.800 0.00% 0
26-07-28 NOK 2.800 0.00% 8,400
26-07-27 NOK 2.800 0.00% 23,610
26-07-24 NOK 2.800 0.00% 0
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Annual profits - Rate of surprise